Pharma and healthcare funding declines by 85.83 per cent in february 2025

Investment in the sector drops to $42.5 million, marking one of the lowest-funded months in the past year
Pharma and healthcare funding declines by 85.83 per cent in february 2025

According to Tracxn report, funding in the healthcare and pharma sector declined by 85.83 per cent to $42.5 million in February 2025, compared to $300 million in January 2025. The sector also saw a 78.86 per cent decrease in funding compared to the $201 million raised in February 2024. This decline places February 2025 among the lowest-funded months in the past 12 months for the sector.

Early-stage rounds accounted for the majority of investments in February 2025, raising $34.6 million, which constituted 85.1 per cent of the total funding. Seed-stage funding contributed $7.87 million, making up 18.5 per cent of the overall investment.

MOC and Apex Kidney Care secured some of the largest funding rounds in February 2025, raising $18 million and $9 million, respectively. Elevation Capital, Endiya Partners, and Good Capital were among the most active investors during the period.

 

Apex Kidney CareElevation CapitalEndiya PartnersHealthcare industryinvestmentmarketMOCpharma
Comments (0)
Add Comment